checkAd

    EQS-Adhoc  117  0 Kommentare COSMO PHARMACEUTICALS N.V. AND CASSIOPEA S.P.A. PUBLISH DEFINITIVE FINAL RESULTS OF PUBLIC EXCHANGE OFFER FOR ALL PUBLICLY HELD SHARES OF CASSIOPEA S.P.A.

    EQS-Ad-hoc: Cosmo Pharmaceuticals N.V. / Key word(s): Takeover
    COSMO PHARMACEUTICALS N.V. AND CASSIOPEA S.P.A. PUBLISH DEFINITIVE FINAL RESULTS OF PUBLIC EXCHANGE OFFER FOR ALL PUBLICLY HELD SHARES OF CASSIOPEA S.P.A.

    07-Dec-2021 / 06:01 GMT/BST
    Release of an ad hoc announcement pursuant to Art. 53 LR
    The issuer is solely responsible for the content of this announcement.


    Ad hoc announcement pursuant to Art. 53 LR

    Dublin, Ireland and Lainate, Italy - 7 December 2021 - Cosmo Pharmaceuticals N.V. (SIX: COPN) ("Cosmo") and Cassiopea S.p.A. (SIX: SKIN) ("Cassiopea") today announced the definitive final results for the public exchange offer by Cosmo in accordance with articles 125 et seq. of the Federal Act on Financial Markets Infrastructure and Market Conduct in Securities and Derivatives Trading of 19 June 2015 for all publicly held registered shares in Cassiopea ("Offer"). 

    Upon expiration of the additional acceptance period on 2 December 2021, 16:00 (CET), the definitive final results indicate that a total of 5'366'250 Cassiopea shares have been tendered to Cosmo under the Offer, amounting to approximately 93.4% of the Cassiopea shares covered by the Offer, which together with the Cassiopea shares already held by Cosmo equates to approximately 96.5% of the Cassiopea shares currently issued.

    The settlement of the Offer is currently expected to take place on 17 December 2021. The payment of the cash compensation for any fractional shares is expected to take place on 23 December 2021.

    The Offer is subject to the offer restrictions set out in the offer prospectus dated 4 October 2021. 

    About Cosmo Pharmaceuticals
    Cosmo is a specialty pharmaceutical company focused on developing and commercialising products to treat selected gastrointestinal disorders and improve endoscopy quality measures through aiding the detection of colonic lesions. Cosmo has also developed medical devices for endoscopy and has a partnership with Medtronic for the global distribution of GI Genius(TM) its artificial intelligence device that uses artificial intelligence to help detect potential signs of colon cancer. Cosmo has licensed Aemcolo(R) to Red Hill Biopharma Ltd. for the US and has licensed Relafalk(R) to Dr. Falk Gmbh for the EU and other countries. For additional information on Cosmo and its products please visit the Company's website: www.cosmopharma.com

    Seite 1 von 7


    EQS Group AG
    0 Follower
    Autor folgen

    Verfasst von EQS Group AG
    EQS-Adhoc COSMO PHARMACEUTICALS N.V. AND CASSIOPEA S.P.A. PUBLISH DEFINITIVE FINAL RESULTS OF PUBLIC EXCHANGE OFFER FOR ALL PUBLICLY HELD SHARES OF CASSIOPEA S.P.A. EQS-Ad-hoc: Cosmo Pharmaceuticals N.V. / Key word(s): Takeover COSMO PHARMACEUTICALS N.V. AND CASSIOPEA S.P.A. PUBLISH DEFINITIVE FINAL RESULTS OF PUBLIC EXCHANGE OFFER FOR ALL PUBLICLY HELD SHARES OF CASSIOPEA S.P.A. 07-Dec-2021 / 06:01 GMT/BST …